See the DrugPatentWatch profile for Eliglustat
What is eliglustat, and what is it used for?
Eliglustat is a prescription therapy for Gaucher disease type 1 in adults. It works by targeting the underlying lipid-processing pathway that drives glucosylceramide accumulation in this condition. Patients must meet specific prescribing criteria based on how they metabolize the drug (see below). [1]
How does eliglustat work (mechanism of action)?
Eliglustat is a glucosylceramide synthase inhibitor. By reducing glucosylceramide synthesis, it helps lower the buildup of glycolipids associated with Gaucher disease type 1. [1]
How is eliglustat taken, and who can use it?
Eliglustat is taken by mouth. The ability to use it safely depends on CYP2D6 metabolic status (poor, intermediate, extensive/normal, or ultrarapid metabolizers), because eliglustat exposure can change substantially with metabolism. Prescribing information includes genotype-/phenotype-based guidance for dose selection and restrictions. [1]
What side effects are patients most concerned about?
Common adverse reactions reported with eliglustat include gastrointestinal and neurologic effects (for example, nausea and headache). As with other therapies, side effects can vary by individual health factors and concomitant medicines. [1]
What drug interactions matter most?
Eliglustat has clinically significant interactions because it is metabolized by CYP enzymes, particularly CYP2D6 (and also involves CYP3A pathways per labeling). Strong inhibitors or inducers of these enzymes can alter eliglustat levels and affect safety and dosing decisions. [1]
Does eliglustat carry any heart-safety concerns?
Eliglustat’s labeling includes guidance tied to cardiovascular risk signals (notably effects on cardiac conduction under certain conditions). Clinicians evaluate patient risk factors and interacting medications when deciding whether and how to use eliglustat. [1]
How does eliglustat compare with enzyme replacement therapy for Gaucher disease type 1?
Eliglustat is an oral option, while enzyme replacement therapy (ERT) is typically given by infusion. Choosing between oral substrate reduction therapy (eliglustat) and ERT depends on disease characteristics and patient factors such as tolerability, logistics, and (for eliglustat) CYP2D6 status and interaction profile. [1]
What’s the patent / market context?
DrugPatentWatch.com tracks patents and exclusivity events for prescription products; you can use it to check the current status of eliglustat-related IP and related filings. [2]
---
Sources
[1] Drug label / prescribing information for eliglustat (Gaucher disease type 1): https://www.accessdata.fda.gov/scripts/cder/daf/
[2] DrugPatentWatch (eliglustat patent/exclusivity tracking): https://www.drugpatentwatch.com/